Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shannon Townsend

Physician Assistant, Medical Mechanicsville, VA Physician Assistant

NPI 1710110465 CMS profile 10553577

8262 Atlee Rd, Suite 202, Mechanicsville, VA 23116

Open in the dashboard

General payments

$9,617

469 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Townsend of Mechanicsville, VA is reported in the CMS Open Payments database as having received $9,617 across 469 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,014 89
2024 General $2,772 136
2023 General $1,792 79
2022 General $1,458 82
2021 General $1,581 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Townsend
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Shannon Townsend were reported at $2,014. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Shannon Townsend Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,581 $156 $41–$563 $132
2022 $1,458 $185 $55–$649 $149
2023 $1,792 $199 $58–$717 $160
2024 $2,772 $206 $62–$740 $164
2025 $2,014 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,799 147 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,204 68 payments
  3. Janssen Biotech, Inc. $880 44 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $756 45 payments
  5. Genzyme Corporation $734 23 payments
  6. Ardelyx, Inc. $556 23 payments
  7. Pfizer Inc. $389 20 payments
  8. QOL Medical, LLC $384 17 payments
  9. Ferring Pharmaceuticals Inc. $262 10 payments
  10. Celgene Corporation $213 13 payments
  11. Other $1,439 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,484 466 payments
  2. Education $133 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,116 60 payments
  2. SKYRIZI $894 44 payments
  3. XIFAXAN $717 35 payments
  4. ENTYVIO $585 36 payments
  5. DUPIXENT $579 21 payments
  6. STELARA $566 25 payments
  7. LINZESS $563 33 payments
  8. IBSRELA $556 23 payments
  9. HUMIRA $549 25 payments
  10. CREON $489 28 payments
  11. Other $4,643 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,071

Median for Physician Assistant: 241

Drug cost

$1,079,633

Median for Physician Assistant: $4,110

Branded share of claims

36.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 23 $645,195
Creon Lipase/Protease/Amylase Brand 35 $148,217
Zenpep Lipase/Protease/Amylase Brand 14 $122,052
Linzess Linaclotide Brand 59 $70,619
Xifaxan Rifaximin Brand 17 $38,384
Trulance Plecanatide Brand 13 $15,013
Mesalamine Generic 18 $9,846
Dexlansoprazole Dr Dexlansoprazole Brand 30 $6,055
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 31 $5,188
Omeprazole Generic 199 $2,872

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$47,525

Medicare's payments for the services billed

Medicare patients

374

Average age 75

Services billed

590

245 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 32%
Ischemic heart disease 31%
Depression 25%
Chronic kidney disease 22%
Osteoporosis 20%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $240
$240 17 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $224
$224 — —
RINVOQ
  • AbbVie, Inc. $213
$213 — —
SKYRIZI
  • AbbVie, Inc. $212
$212 — —
DUPIXENT
  • GENZYME CORPORATION $195
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

469 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record